Theranos Limits Blood Technology to Single Test Out of 200

Theranos Inc., the heralded Silicon Valley blood-testing startup facing scrutiny over the accuracy of its technology, said it has scaled back the use of proprietary finger-pricking technique to a single test out of the 200 it offers.

The decision limits the use of a technology that has helped Theranos raise venture-capital funding at a valuation of about $10 billion and has drawn interest from high-profile partners. Now Theranos is using the same blood-testing equipment as competitors it’s attempting to challenge, such as Quest Diagnostics Inc. and Laboratory Corp. of America Holdings.

The move is temporary and is part of a ...